Dilip Shah1, Pragnya Das1, Suchismita Acharya2,3, Beamon Agarwal4, Dale J Christensen5,6, Stella M Robertson2,7, Vineet Bhandari1. 1. Division of Neonatology, Department of Pediatrics, Drexel University, Philadelphia, PA 19197, USA. 2. AyuVis Research, Inc., 1120 South Freeway, Fort Worth, TX 76104, USA. 3. Pharmacology & Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76104, USA. 4. GenomeRxUS, Secane, PA 19018, USA. 5. Dale J. Christensen Consulting LLC, Cary, NC 27511, USA. 6. Division of Hematology, Department of Medicine, Duke University Medical Center, Durham, NC 27722, USA. 7. Arrochar Consulting LLC, Fort Worth, TX 76104, USA.
Abstract
BACKGROUND: Acute lung injury (ALI) or its most advanced form, acute respiratory distress syndrome (ARDS) is a severe inflammatory pulmonary process triggered by a variety of insults including sepsis, viral or bacterial pneumonia, and mechanical ventilator-induced trauma. Currently, there are no effective therapies available for ARDS. We have recently reported that a novel small molecule AVR-25 derived from chitin molecule (a long-chain polymer of N-acetylglucosamine) showed anti-inflammatory effects in the lungs. The goal of this study was to determine the efficacy of two chitin-derived compounds, AVR-25 and AVR-48, in multiple mouse models of ALI/ARDS. We further determined the safety and pharmacokinetic (PK) profile of the lead compound AVR-48 in rats. METHODS: ALI in mice was induced by intratracheal instillation of a single dose of lipopolysaccharide (LPS; 100 µg) for 24 h or exposed to hyperoxia (100% oxygen) for 48 h or undergoing cecal ligation and puncture (CLP) procedure and observation for 10 days. RESULTS: Both chitin derivatives, AVR-25 and AVR-48, showed decreased neutrophil recruitment and reduced inflammation in the lungs of ALI mice. Further, AVR-25 and AVR-48 mediated diminished lung inflammation was associated with reduced expression of lung adhesion molecules with improvement in pulmonary endothelial barrier function, pulmonary edema, and lung injury. Consistent with these results, CLP-induced sepsis mice treated with AVR-48 showed a significant increase in survival of the mice (80%) and improved lung histopathology in the treated CLP group. AVR-48, the lead chitin derivative compound, demonstrated a good safety profile. CONCLUSION: Both AVR-25 and AVR-48 demonstrate the potential to be developed as therapeutic agents to treat ALI/ARDS.
BACKGROUND:Acute lung injury (ALI) or its most advanced form, acute respiratory distress syndrome (ARDS) is a severe inflammatory pulmonary process triggered by a variety of insults including sepsis, viral or bacterial pneumonia, and mechanical ventilator-induced trauma. Currently, there are no effective therapies available for ARDS. We have recently reported that a novel small molecule AVR-25 derived from chitin molecule (a long-chain polymer of N-acetylglucosamine) showed anti-inflammatory effects in the lungs. The goal of this study was to determine the efficacy of two chitin-derived compounds, AVR-25 and AVR-48, in multiple mouse models of ALI/ARDS. We further determined the safety and pharmacokinetic (PK) profile of the lead compound AVR-48 in rats. METHODS: ALI in mice was induced by intratracheal instillation of a single dose of lipopolysaccharide (LPS; 100 µg) for 24 h or exposed to hyperoxia (100% oxygen) for 48 h or undergoing cecal ligation and puncture (CLP) procedure and observation for 10 days. RESULTS: Both chitin derivatives, AVR-25 and AVR-48, showed decreased neutrophil recruitment and reduced inflammation in the lungs of ALI mice. Further, AVR-25 and AVR-48 mediated diminished lung inflammation was associated with reduced expression of lung adhesion molecules with improvement in pulmonary endothelial barrier function, pulmonary edema, and lung injury. Consistent with these results, CLP-induced sepsismice treated with AVR-48 showed a significant increase in survival of the mice (80%) and improved lung histopathology in the treated CLP group. AVR-48, the lead chitin derivative compound, demonstrated a good safety profile. CONCLUSION: Both AVR-25 and AVR-48 demonstrate the potential to be developed as therapeutic agents to treat ALI/ARDS.
Authors: John C Densmore; Paul R Signorino; Jingsong Ou; Ossama A Hatoum; J Jordi Rowe; Yang Shi; Sushma Kaul; Deron W Jones; Robert E Sabina; Kirkwood A Pritchard; Karen S Guice; Keith T Oldham Journal: Shock Date: 2006-11 Impact factor: 3.454
Authors: Gordon D Rubenfeld; Ellen Caldwell; Eve Peabody; Jim Weaver; Diane P Martin; Margaret Neff; Eric J Stern; Leonard D Hudson Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: S Kritas; P Conti; G Ronconi; A Caraffa; C Gallenga; R Ross; I Frydas Journal: J Biol Regul Homeost Agents Date: 2020 March-April, Impact factor: 1.711
Authors: Andreas von Knethen; Ulrike Heinicke; Volker Laux; Michael J Parnham; Andrea U Steinbicker; Kai Zacharowski Journal: Biomedicines Date: 2022-01-04